CuraCell Receives German Approval for Phase I/IIa Trial of CC-38 TIL Therapy in Metastatic Cancers
Key Insights
CuraCell (search) has received approval from Germany's Paul-Ehrlich-Institut to begin a Phase I/IIa clinical trial of CC-38 (search), an autologous tumor-infiltrating lymphocyte therapy for metastatic colorectal and prostate cancers.
The open-label study will enroll up to 16 patients with advanced solid tumors at Krankenhaus Nordwest (search) in Frankfurt, with primary objectives focused on assessing safety and tolerability.
CC-38 (search) is based on CuraCell (search)'s CytoPLY platform, which aims to improve tumor-specific T-cell functionality and diversity compared to conventional interleukin-2-based approaches.
Swedish immunotherapy company CuraCell (search) has received approval from Germany's Paul-Ehrlich-Institut (PEI) to begin a Phase I/IIa clinical trial of its tumor-infiltrating lymphocyte (TIL) therapy CC-38 (search) for patients with metastatic colorectal and prostate cancer (search). The trial is scheduled to start in the latter half of this year at Krankenhaus Nordwest (search) in Frankfurt.
Trial Design and Objectives
The open-label study will recruit up to 16 patients with advanced solid tumors, specifically targeting prostate and colorectal cancers. The primary objectives will focus on assessing safety and tolerability of the therapy, while secondary endpoints will evaluate preliminary anti-tumor activity and immune responses. The study will also investigate the possibility of repeated administration of CC-38 (search).
CytoPLY Platform Technology
CC-38 (search) is based on CuraCell (search)'s proprietary CytoPLY platform, which aims to improve tumor-specific T-cell functionality and diversity compared to standard methods. The therapy involves isolating and expanding tumor-reactive lymphocytes directly from patients' tumors to enhance the immune system's capacity to target cancer.
According to the company, the CytoPLY platform allows for quicker expansion of tumor-killing T cells compared to conventional interleukin-2 (IL-2)-based approaches. The platform seeks to expand the TCR repertoire to recognize a wider array of neoantigens and to boost cytokine production, thereby prolonging the survival and anti-tumor activity of T-cells (search).
Company Leadership Response
"This CTA approval marks a major milestone for CuraCell (search) and affirms the strength of our science and clinical strategy," said Jonas Båtelson, CEO of CuraCell. "Our dedicated team, together with our expert collaborators, has worked tirelessly to advance our first TIL therapy from bench to bedside. This is a big step forward in our mission to provide curative treatments for the toughest and most deadly solid tumors."
CuraCell (search) specializes in developing immunotherapies for hard-to-treat solid tumors, with operations in both Sweden and Germany. The company's focus on TIL therapy represents an approach that leverages the patient's own immune system through the expansion of lymphocytes that are tumor-reactive and directly taken from the tumor.